Serina Therapeutics, Inc. (SER) financial statements and ratios from SEC XBRL: revenue $130000.00 (TTM), net margin -14755.4%, revenue growth 132.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $130000.00 |
| Net Margin | -14755.4% |
| Revenue Growth (YoY) | 132.1% |
| EPS Growth (YoY) | 26.5% |
| FCF Growth (YoY) | 5.0% |
| Price / Book | 3.88 |
| Price / Sales | 558.81 |
| FCF Yield | -44.7% |
| Altman Z-Score | -20.72 (distress) |
| Sector P/E (Healthcare) | 21.7 |
SER overview · SER earnings · SER KPIs · SER investor relations · SER ownership · SER peers · SER filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.